Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02240017
Other study ID # 13 URO 02
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date January 21, 2015
Est. completion date July 15, 2019

Study information

Verified date August 2019
Source Institut Claudius Regaud
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II/III, multicenter, randomized study which includes 420 patients on six years + 3 years follow up. 92 patients will be included during the phase II ; additional 328 patients will be included.

Patients with an advanced or metastatic urothelial cancer with impaired renal function will be randomized in one of the two following chemotherapy arm:

- Fractionated Cisplatin + Gemcitabine.

- Carboplatin + Gemcitabine.

The main objective of the part II study will be to evaluate the efficacy and the safety of a chemotherapy with a doublet platinum salt compound/Gemcitabine with fractionated Cisplatin or Carboplatin in this population.

The main objective of the part III study will be to compare the efficacy in terms of overall survival of a chemotherapy with a doublet platinum salt/Gemcitabine with fractionated Cisplatin or Carboplatin in this population.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date July 15, 2019
Est. primary completion date April 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. . Age < or = 18 years, patients aged 75 years or more will benefit from a geriatric assessment.

2. . Advanced or metastatic urothelial cancer confirmed histologically or cytologically.

3. . Patients liable to receive a first -line chemotherapy for advanced or metastatic urothelial carcinoma.

4. . Measurable disease according to RECIST criteria V1.1.

5. . Patients who received neoadjuvant or adjuvant chemotherapy based on platinum salt must have completed treatment at least 6 months before entering the study.

6. . Performance status < or = 2.

7. . Life expectancy > 3 months.

8. . Patients with creatinine clearance between 40 and 60 ml / min ( according to Cockcroft and Gault ).

9. . Patients having no contra-indication to overhydration.

10. . Satisfactory hematological tests: Neutrophils > 1.5 G / l Platelets > 150 G / l , hemoglobin = 10 g / dl.

11. . Satisfactory liver function tests: total bilirubin < 1.5 x ULN (upper limit of normal), AST (aspartate aminotransferase) and ALT (alanine aminotransferase)<or = 2.5 x ULN (or 5 x ULN if liver metastases).

12. . In case of prior radiotherapy, a minimum of 14 days must relapse between the end of radiotherapy and study entry.

13. . For women of childbearing age , use an effective contraceptive method to study entry and for the duration of the study and 6 months after the last dose of study treatment ; For sexually active fertile men having a partner of childbearing age using effective contraception for the duration of the study and 6 months after the last dose of study treatment.

14. . Patient affiliated to a social security system in France.

15. . Patient signed informed consent before inclusion in the study and before any specific procedure for the study.

Exclusion Criteria:

1. . Any concomitant or previous malignancy within 5 years prior to the study ( with the exception of basal cell or squamous cell carcinoma in situ).

2. . Pregnant or lactating women.

3. . Patients with brain metastases or meningeal or symptoms suggestive of such secondary locations.

4. . Bisphosphonate or Denosumab treatment initiated within 28 days prior to randomization into the study or patient who have started such treatment during the study ( a bisphosphonate or denosumab treatment initiated within a period longer than 28 days before randomization may be continued without change during the study ).

5. . Other concomitant cancer (radiation therapy, radiopharmaceutical agent chemotherapy).

6. . Patients with uncontrolled infection.

7. . Patients with peripheral neuropathy grade> 1, whatever the origin or patients with hearing loss.

8. . Patient with unstable disease (eg: unstable diabetes, poorly controlled hypertension , congestive heart failure or myocardial infarction within 3 months prior to study entry).

9. . Known hypersensitivity to study drugs.

10. . Treatment with any other investigational drug within 30 days before inclusion.

11. . Any psychological condition , familial, sociological or geographical not to comply with medical monitoring and / or procedures in the study protocol.

12. . Patient protected by law.

Study Design


Intervention

Drug:
Carboplatin
Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
Fractionated Cisplatin
Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
Gemcitabine
Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.

Locations

Country Name City State
France INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Paul Papin Angers
France Chru Besancon - Hopital Jean Minjoz Besançon
France Institut Bergonie Bordeaux
France Centre Francois Baclesse Caen
France Centre Georges Francois Leclerc Dijon
France CH VERSAILLES - Hôpital André Mignot Le Chesnay
France CHU LIMOGES - Hôpital Dupuytren Limoges
France Centre Leon Berard Lyon
France Institut Paoli Calmettes Marseille
France Ch Mont de Marsan Mont de Marsan
France Institut Regional Du Cancer Montpellier Montpellier
France Ap-Hp-Hopital Saint-Louis Paris
France INSTITUT DE CANCEROLOGIE DE L'OUEST - Site René Gauducheau Saint-Herblain
France Institut de Cancerologie Lucien Neuwirth Saint-Priest en Jarez
France CHU de STRASBOURG Strasbourg
France Institut Claudius Regaud Toulouse
France Chru Tours Tours
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Institut Claudius Regaud

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase II: Efficacy - Rate of non progression at the end of treatment (C6D21). Progression is defined according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria V1.1. 5 years.
Primary Phase III: Overall survival (in months). Overall survival is defined as the time from randomization until death or last follow up news (censured data). 9 years.
Primary Phase II: Tolerance - Percentage of patients for whom at least one of the 3 defined tolerance criteria (see description) is observed. Defined tolerance criteria :
Postponement of chemotherapy > or = 2 weeks.
Alteration of renal function.
Need to decrease twice Gemcitabine dose on day 1 for : NCI CTC (National Cancer Institut Common Toxicity Criteria) grade III or IV non-hematologic toxicity, hematologic toxicity.
5 years.
Secondary Phase II and III: Objective response. Objective response (ie complete or partial response) will be evaluated according to RECIST v1.1 criteria. Phase II: 5 years ; Phase III: 9 years.
Secondary Phase II and III: Tolerance according to NCI toxicity scale (version 4.0). Phase II: 5 years ; Phase III: 9 years.
Secondary Phase II and III: Geriatric evaluation using questionnaires. The geriatric assessment will be evaluate using the following questionnaires: G8 (oncodage) , ADL (activity of daily living), CIRSG (cumulating illness rating scale geriatric) , MMS (mini-mental score), IADL (instrumental activities of daily living), GDS (geriatric depression scale), MNA (mini-nutritional assessment). Phase II: 5 years ; Phase III: 9 years.
Secondary Phase II and III: Quality of life using the EORTC QLQ - C30 questionnaire (European Organization for research and treatment of Cancer - Quality of life questionnaire). Phase II: 5 years ; Phase III: 9 years.
Secondary Phase II and III: Pharmacokinetics - Platin concentrations At cycles 1 and 2 day 1 - 5 mn before the end of infusion, one hour after the end of infusion, 3 hours (arm A) or 4 hours (arm B) after the end of infusion.
Secondary Phase II and III: Pharmacogenetics, exploration of cytidine deaminase activity and study of its genetic polymorphisms. Prior to the initial dose on cycle 1 day 1.
Secondary Phase II and III: Progression free survival. Progression free survival will be evaluated according to RECIST v1.1 criteria. Phase II: 5 years ; phase III: 9 years.
Secondary Phase II and III: Overall survival. Overall survival is defined as the time from randomization until death from all causes combined. Phase II: 5 years ; Phase III: 9 years.
Secondary Phase II and III: Time to treatment failure. Time to treatment failure is defined as the time from randomization to treatment discontinuation, whatever its cause. Phase II: 5 years ; Phase III: 9 years.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03682068 - Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer Phase 3
Recruiting NCT05101096 - Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02826564 - Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer Phase 1
Completed NCT01963052 - ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer Phase 1
Not yet recruiting NCT05390645 - A Study of MFA-370 in Patients With Metastatic Urothelial Cancer Phase 1/Phase 2
Recruiting NCT03745911 - Paclitaxel and TAK-228 in Urothelial Carcinoma Phase 2
Completed NCT03390595 - Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma Phase 2
Completed NCT03451331 - Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT04995419 - A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy Phase 2
Completed NCT03679767 - A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Phase 2
Recruiting NCT06225596 - Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Phase 2/Phase 3
Recruiting NCT03547973 - Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Phase 2
Completed NCT03070990 - A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Phase 1
Completed NCT03448718 - Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Phase 2